Vertex Pharmaceuticals Inc. has acquired worldwide development and commercialization rights to Concert Pharmaceuticals Inc.'s edited version of its own market-changing cystic fibrosis therapy Kalydeco (ivacaftor) in a move to defend its market-leading CF portfolio.
The transaction takes away Concert's rights to its lead development program, but the deal is transformative for the company in...








